The potential importance of CD1d-restricted V124-invariant Natural Killer T cells (NKTs) for antitumor immunity and immunotherapy has been demonstrated in multiple models of cancer as well as in recent oncology clinical trials. Recent findings by our own and other labs suggest that while NKTs lack direct effect on tumor cells in the majority of solid tumors, they mediate antitumor immune responses via specific interactions with CD1d- positive subsets of myelomonocytic cells. We have recently demonstrated that one way by which NKTs may control tumor growth is by specific recognition and killing of tumor-associated macrophages (TAMs), thereby removing essential IL-6-STAT3-mediated growth support from tumor cells. Our preliminary data suggests that there is a stepwise CCL2- and CCL20-mediated NKT-cell localization to the tumor site, in which NKTs interact with CD1d+ TAMs and immature dendritic cells (iDCs) in the context of the tumor microenvironment. We have found that monocytic cells strongly up-regulate CCL20 expression in response to hypoxia-mediated signal(s) from neuroblastoma (NB) cells, leading us to hypothesize that tumor hypoxia regulates NKT cell localization and innate antitumor activity in NB. Because CCL20 is also a potent chemoattractant for iDCs, NKT cell interaction with CD1d+ iDCs at the tumor site may lead to the generation of protective adaptive immune response. The following specific aims will test these hypotheses: 1) to examine the mechanism by which tumor hypoxia regulates NKT cell localization and innate anti-tumor activity in NB;2) to examine the role of NKT cell interaction with CD1d+ myeloid cells at the tumor site in the mechanism of adaptive anti-tumor immune response against NB. Using established in our lab humanized NB/TAM model and human ex vivo expanded NKTs, we will evaluate the role of hypoxic signaling in CCL20-dependent NKT-cell co-localization with TAMs and the role of NKT cell interaction with TAMs in the mechanism of innate NKT cell-mediated antitumor activity. Then, using NB9464-OVA murine NB model, we will study how NKT-cell interaction with CD1d+ myeloid cells at the tumor site may lead to activation and maturation of iDCs, followed by improved presentation of tumor-derived antigens to CD8 T cells and generation of protective adaptive immunity. The results of the proposed investigation are expected to reveal novel mechanisms that govern NKT-cell localization to the tumor site and their function in the antitumor immunity.

Public Health Relevance

The proposed investigation will continue to investigate the mechanism of NKT cell homing to the tumor site in neuroblastoma, one of the most common and deadly type of cancer in children. We will examine how NKT cells regulate innate and adaptive antitumor immune responses in the context of the tumor microenvironment. The results may lead to new immunotherapeutic strategies and clinical trials in neuroblastoma and other types of cancer in children and adults.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA116548-08
Application #
8386637
Study Section
Transplantation, Tolerance, and Tumor Immunology (TTT)
Program Officer
Howcroft, Thomas K
Project Start
2005-07-01
Project End
2015-11-30
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
8
Fiscal Year
2013
Total Cost
$220,389
Indirect Cost
$79,565
Name
Baylor College of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Heczey, Andras; Liu, Daofeng; Tian, Gengwen et al. (2014) Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 124:2824-33
Xu, Xin; Hegazy, Wael A H; Guo, Linjie et al. (2014) Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system. Cancer Res 74:6260-70
Liu, Daofeng; Song, Liping; Brawley, Vita S et al. (2013) Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. Clin Immunol 149:55-64
Hsu, Danielle M; Agarwal, Saurabh; Benham, Ashley et al. (2013) G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res 73:4134-46
Metelitsa, Leonid S (2011) Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol 140:119-29
Xiong, Guosheng; Husseiny, Mohamed I; Song, Liping et al. (2010) Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. Int J Cancer 126:2622-34
Ara, Tasnim; Song, Liping; Shimada, Hiroyuki et al. (2009) Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 69:329-37
Song, Liping; Asgharzadeh, Shahab; Salo, Jill et al. (2009) Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest 119:1524-36
Song, Liping; Ara, Tasnim; Wu, Hong-Wei et al. (2007) Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J Clin Invest 117:2702-12
Lu, Xuequan; Song, Liping; Metelitsa, Leonid S et al. (2006) Synthesis and evaluation of an alpha-C-galactosylceramide analogue that induces Th1-biased responses in human natural killer T cells. Chembiochem 7:1750-6